As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Fortress Biotech, Inc. The largest reported stake is Lindsay A. Rosenwald, M.D.'s, at 20.7%. 4 filings are on record since March 20, 2026 (Schedule 13D/A, March 20, 2026).
Sell to companies like Fortress Biotech, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 2,165,122 · Sole dispositive: 0 · Shared dispositive: 2,165,122 · SCHEDULE 13G/A, 2026-10-29
- · Holder: Integrated Core Strategies (US) LLC · Percent: 5.3% · SCHEDULE 13G
- · Holder: Highbridge Capital Management, LLC · Percent: 7.8% · SCHEDULE 13G/A
- · Holder: Lindsay A. Rosenwald, M.D. · Percent: 20.7% · SCHEDULE 13D/A
Fortress Biotech, Inc. has 4 Schedule 13D or 13G filings on record since 2026-03-20. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Lindsay A. Rosenwald, M.D. | 20.7% | 6,917,715 | SCHEDULE 13D/A, 2026-03-20 | 2026-03-18 |
| Highbridge Capital Management, LLC | 7.8% | 2,734,654 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Integrated Core Strategies (US) LLC | 6.5% | 2,165,122 | SCHEDULE 13G/A, 2026-10-29 | 2026-09-30 |
Holding shares or following this stake? See who's behind Fortress Biotech, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Fortress Biotech, Inc. and the records around it.
Fortress Biotech, Inc. elsewhere on the record
Companies that share a holder
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Watch Fortress Biotech, Inc.
Get an email when Fortress Biotech, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Fortress Biotech, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Fortress Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Fortress Biotech, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Integrated Core Strategies (US) LLC | 0 | 2,165,122 | 0 | 2,165,122 | SCHEDULE 13G/A, 2026-10-29 |
| Millennium Management LLC | 0 | 2,165,401 | 0 | 2,165,401 | SCHEDULE 13G/A, 2026-10-29 |
| Millennium Group Management LLC | 0 | 2,165,401 | 0 | 2,165,401 | SCHEDULE 13G/A, 2026-10-29 |
| Israel A. Englander | 0 | 2,165,401 | 0 | 2,165,401 | SCHEDULE 13G/A, 2026-10-29 |
The latest filing identifies Fortress Biotech, Inc. by CUSIP 34960Q307 and gives its principal executive office as 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 (SCHEDULE 13G/A, 2026-10-29).
Purpose of Transaction (Item 4)
Lindsay A. Rosenwald, M.D.
The Reporting Person was granted the shares of Common Stock on each of January 1, 2025 and March 18, 2026 pursuant to the LTIP and Award Agreement and upon the determination that the Reporting Person had achieved 100% of the relevant goals and objectives established by the Compensation Committee of the Issuer's Board. The Reporting Person does not have any present plans or proposals that relate to or would result in: (i) the acquisition by any person of additional securities of Issuer, or the disposition of securities of Issuer; (ii) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving Issuer or any of Issuer's subsidiaries; (iii) a sale or transfer of a material amount of assets of Issuer or any of Issuer's subsidiaries; (iv) any change in the present board of directors or management of Issuer; (v) any material change in the present capitalization or dividend policy of Issuer; (vi) any other material change in Issuer's business or corporate structure; (vii) changes in Issuer's charter, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of Issuer by any person; (viii) causing a class of securities of Issuer to be de-listed from a national securities exchange or to cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association; (ix) a class of equity securities of Issuer becoming eligible for termination of registration …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-03-20; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-20 | Lindsay A. Rosenwald, M.D. | 20.7% | SCHEDULE 13D/A |
| 2026-05-15 | Highbridge Capital Management, LLC | 7.8% | SCHEDULE 13G/A |
| 2026-09-01 | Integrated Core Strategies (US) LLC | 5.3% | SCHEDULE 13G |
| 2026-10-29 | Integrated Core Strategies (US) LLC | 6.5% | SCHEDULE 13G/A |
Questions about who owns Fortress Biotech, Inc.
Who owns Fortress Biotech, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Fortress Biotech, Inc.: Lindsay A. Rosenwald, M.D. (20.7%, Schedule 13D/A, filed 2026-03-20), Highbridge Capital Management, LLC (7.8%, Schedule 13G/A, filed 2026-05-15) and Integrated Core Strategies (US) LLC (6.5%, Schedule 13G/A, filed 2026-10-29).
Who are the largest shareholders of Fortress Biotech, Inc.?
By the share each holder's latest filing reports, the largest holders of Fortress Biotech, Inc. on this page are Lindsay A. Rosenwald, M.D. (20.7%), Highbridge Capital Management, LLC (7.8%) and Integrated Core Strategies (US) LLC (6.5%).
When did Lindsay A. Rosenwald, M.D. buy into Fortress Biotech, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lindsay A. Rosenwald, M.D. on this page is the Schedule 13D/A, filed 2026-03-20, reporting 20.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Fortress Biotech, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.